gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · LENZHealthcareBiotechnology

LENZ Therapeutics, Inc. Common Stock (LENZ)

$3.46−1.14%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$3.46▼ 87.66% in range
Nov 4, 2025Low $3.05 · High $31.94Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

LENZ Therapeutics closed at $3.46 on Nov 4, down 1.14%, 89.2% below its 52-week closing high. Volume of 1.2M shares was 1.07× its 20-day average (close to normal).

Split-adjusted performance: -8.7% over one month, -64.3% over six months, -87.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $5.49M, up 9.7% from a year earlier, with a net margin of -581.8%.

Short interest was 9.1M shares at the Oct 15 settlement, down 13.9% from the prior report (46.7% of float, 11.8 days to cover).

Market cap$108.7M31.4M shares
Revenue · quarter$5.5M+9.7% YoY
Diluted EPS$-1.02—
P/E · TTM—P/S 5.1×
Net margin-581.8%Gross 94.9%
Dividend yieldNone
52-week range3.05 – 31.94−89.2% from high
Volume1.2M1.07× 20-day avg
Volatility · 60d75.9%Annualised
Short % of float46.7%11.8 days to cover
Net cash$220.0MCash $220.0M
Next earnings—Not scheduled
Split-adjusted performance
1W +7.8%1M −8.7%3M −33.7%6M −64.3%YTD −78.4%1Y −87.6%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum15
Revenue growth54
Net margin39
Value (low P/E)—
Size34

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short9.1M−13.9% vs prior
Days to cover11.8Settled Oct 15
% of float46.7%
Short vol. 10d44.3%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
LENZLENZ Therapeutics$3.46−1.14%−64.3%+9.7%−581.8%—$108.7M
BDTXBlack Diamond Therapeutics$1.90+4.97%−32.6%———$109.2MCompare
NMRANeumora Therapeutics$0.5660−0.86%−75.7%———$106.3MCompare
OTLKOutlook Therapeutics$0.4621+0.46%+99.4%−99.4%−233554.9%—$112.5MCompare
VYGRVoyager Therapeutics$1.87+2.19%−55.2%−39.1%−773.2%—$115.2MCompare
ENGNenGene Therapeutics$1.72+6.17%−80.6%———$115.3MCompare
ARMPArmata Pharmaceuticals$3.14+1.62%−65.3%+15.7%2953.8%—$116.8MCompare
AVXLAnavex Life Sciences$1.26+5.00%−62.3%———$116.8MCompare
HUMAHumacyte$0.4500+2.16%−54.2%+34.9%−9064.5%—$125.0MCompare

News about LENZ Therapeutics

All news →
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZGlobeNewswire Inc. · Oct 6, 2026▼ NegativeLENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater ChinaGlobeNewswire Inc. · Jun 7, 2026▲ PositiveWhy Lenz Therapeutics Stock Crashed TodayThe Motley Fool · Mar 24, 2026▼ Negative

Quick answers

What does LENZ Therapeutics do?
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours.
What is LENZ's market cap?
$108.71M, based on the Nov 4 close of $3.46.
Does LENZ Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of LENZ is sold short?
9.1M shares, 46.7% of float, as of Oct 15, 2026.
What sector is LENZ in?
Healthcare, in the Biotechnology industry.

About LENZ Therapeutics

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.

HQ: Solana Beach, CA152 employeesListed Mar 22, 2024lenz-tx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology